DE69026615D1 - Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest - Google Patents

Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest

Info

Publication number
DE69026615D1
DE69026615D1 DE69026615T DE69026615T DE69026615D1 DE 69026615 D1 DE69026615 D1 DE 69026615D1 DE 69026615 T DE69026615 T DE 69026615T DE 69026615 T DE69026615 T DE 69026615T DE 69026615 D1 DE69026615 D1 DE 69026615D1
Authority
DE
Germany
Prior art keywords
pct
complement activation
antibody
hinge region
complement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69026615T
Other languages
English (en)
Other versions
DE69026615T2 (de
Inventor
Terje Michaelsen
Inger Sandlie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STATENS INSTITUTT FOR FOLKEHELSE, OSLO, NO
Original Assignee
Dynal AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynal AS filed Critical Dynal AS
Publication of DE69026615D1 publication Critical patent/DE69026615D1/de
Application granted granted Critical
Publication of DE69026615T2 publication Critical patent/DE69026615T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69026615T 1989-07-18 1990-07-17 Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest Expired - Fee Related DE69026615T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898916400A GB8916400D0 (en) 1989-07-18 1989-07-18 Modified igg3
PCT/EP1990/001172 WO1991001335A1 (en) 1989-07-18 1990-07-17 IgG3 ANTIBODIES WITH SHORTENED HINGE REGION AND A COMPLEMENT ACTIVATION TEST

Publications (2)

Publication Number Publication Date
DE69026615D1 true DE69026615D1 (de) 1996-05-23
DE69026615T2 DE69026615T2 (de) 1996-09-26

Family

ID=10660201

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69026615T Expired - Fee Related DE69026615T2 (de) 1989-07-18 1990-07-17 Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest

Country Status (8)

Country Link
US (1) US5348876A (de)
EP (1) EP0483194B1 (de)
JP (1) JPH05500303A (de)
AT (1) ATE136909T1 (de)
DE (1) DE69026615T2 (de)
DK (1) DK0483194T3 (de)
GB (1) GB8916400D0 (de)
WO (1) WO1991001335A1 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033589B1 (en) 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6893636B2 (en) 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
SI1068241T1 (sl) 1998-04-02 2007-12-31 Genentech Inc Protitelesne variante in njihovi fragmenti
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
KR101077001B1 (ko) * 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6193892B1 (en) 1999-03-03 2001-02-27 Promega Corporation Magnetic separation assembly and method
CA2399940A1 (en) 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
FR2836146B1 (fr) * 2002-02-15 2005-01-07 Urrma R & D IMMUNOGLOBULINE IgG3 MARQUEUR DE PROTECTION CONTRE LES MALADIES VIRALES INFECTIEUSES ET SES UTILISATIONS
US8044180B2 (en) * 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) * 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) * 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) * 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
AU2003287345A1 (en) 2002-10-31 2004-06-07 Genentech, Inc. Methods and compositions for increasing antibody production
US7355008B2 (en) * 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2005000898A2 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
EP1663306A2 (de) * 2003-09-05 2006-06-07 Genentech, Inc. Antikörper mit veränderten effektor-funktionen
EP1699822B1 (de) * 2003-12-30 2008-04-23 MERCK PATENT GmbH Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
US20050255533A1 (en) * 2004-02-10 2005-11-17 Brendan Bioscience, Llc Comprehensive food allergy test
US8309318B2 (en) * 2004-02-10 2012-11-13 Brendan Bioscience, Llc Detection of antigen specific immunocomplexes
WO2005110474A2 (en) * 2004-05-10 2005-11-24 Macrogenics, Inc. HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP2213683B1 (de) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Varianten der Fc Regionen
CN101052654A (zh) * 2004-08-19 2007-10-10 健泰科生物技术公司 具有改变的效应子功能的多肽变体
WO2006028936A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
EP1674479A1 (de) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulierung von Fc-gamma-Rezeptoren zur Optimierung einer Immunotherapie
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) * 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
EP1874816A4 (de) * 2005-04-26 2010-08-25 Medimmune Inc Modulation der antikörpereffektorfunktion mittels manipulation von verbindungsregionen
ES2526811T3 (es) * 2005-08-10 2015-01-15 Macrogenics, Inc. Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos
WO2007106707A2 (en) * 2006-03-10 2007-09-20 Macrogenics, Inc. Identification and engineering of antibodies with variant heavy chains and methods of using same
GB2436616A (en) * 2006-03-29 2007-10-03 Inverness Medical Switzerland Assay device and method
EP2006381B1 (de) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Verfahren zur kontrolle der blut-pharmakokinetik von antikörpern
EP4218801A3 (de) 2006-03-31 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Antikörpermodifizierungsverfahren zur reinigung eines bispezifischen antikörpers
WO2008105886A2 (en) 2006-05-26 2008-09-04 Macrogenics, Inc. HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP2032159B1 (de) * 2006-06-26 2015-01-07 MacroGenics, Inc. Kombination aus fcgammariib-antikörpern und cd20-spezifischen antikörpern sowie verwendungsverfahren dafür
ES2599319T3 (es) * 2006-06-26 2017-02-01 Macrogenics, Inc. Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
EP2047269B1 (de) * 2006-07-14 2014-04-30 Eötvös Lorand University Messung von komplementaktivierungsprodukten auf antigen-mikroarrays
US20080112961A1 (en) * 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
WO2008140603A2 (en) * 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
SG193868A1 (en) 2007-09-26 2013-10-30 Chugai Pharmaceutical Co Ltd Modified antibody constant region
PL2202245T3 (pl) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
WO2009117030A2 (en) * 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
SG189730A1 (en) 2008-04-02 2013-05-31 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
EP3045475B1 (de) 2008-04-02 2017-10-04 MacroGenics, Inc. Bcr-komplex-spezifische antikorper und verfahren zu ihrer verwendung
EP2282770B1 (de) * 2008-06-04 2018-03-07 MacroGenics, Inc. Antikörper mit veränderter bindung an fcrn und verwendungsverfahren dafür
EP2826789A1 (de) 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Variante einer konstanten Region eines Antikörpers
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
WO2011037158A1 (ja) * 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
SI2486141T1 (en) 2009-10-07 2018-06-29 Macrogenics, Inc. FC REGION-CONTAINING POLYPETHYDE, AFFECTING A BETTERED EFFECTORAL FUNCTION, BY CHANGES IN THE SCOPE OF FUKOZILATION AND METHODS FOR THEIR USE
SG183847A1 (en) 2010-03-04 2012-10-30 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
ES2667100T3 (es) 2010-08-02 2018-05-09 Macrogenics, Inc. Diacuerpos covalentes y sus usos
PT2691417T (pt) 2011-03-29 2018-10-31 Roche Glycart Ag Variantes de fc de anticorpos
SG195073A1 (en) 2011-05-21 2013-12-30 Macrogenics Inc Deimmunized serum-binding domains and their use for extending serum half-life
ES2896493T3 (es) 2012-07-13 2022-02-24 Roche Glycart Ag Anticuerpos biespecíficos anti-VEGF/anti-ANG-2 y su uso en el tratamiento de enfermedades vasculares oculares
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
CN111925437A (zh) 2013-03-14 2020-11-13 宏观基因有限公司 与表达激活受体的免疫效应细胞具有免疫反应性的双特异性分子
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2839842A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
EP2840091A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
MX2017004076A (es) 2014-09-29 2017-07-04 Univ Duke Moleculas biespecificas que comprenden un brazo orientado a la envoltura vih-1.
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
EP3398965A4 (de) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Verfahren zur förderung der effizienz der reinigung von polypeptid mit fc-region
EP3442574A4 (de) 2016-04-15 2019-12-11 MacroGenics, Inc. Neuartige b7-h3-bindende moleküle, antikörper-wirkstoff-konjugate davon und verfahren zur verwendung davon

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2840847A1 (de) * 1978-09-20 1980-04-03 Behringwerke Ag Verfahren zum nachweis und zur bestimmung komplementbindender antikoerper
DE3883899T3 (de) * 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
FR2609398A1 (fr) * 1988-04-19 1988-07-15 Zagyansky Yuly Structure de l'igg plus antigene et complement, ses mecanismes et les consequences importantes
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
JP3095168B2 (ja) * 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体

Also Published As

Publication number Publication date
JPH05500303A (ja) 1993-01-28
US5348876A (en) 1994-09-20
ATE136909T1 (de) 1996-05-15
GB8916400D0 (en) 1989-09-06
EP0483194A1 (de) 1992-05-06
DK0483194T3 (da) 1996-05-13
DE69026615T2 (de) 1996-09-26
EP0483194B1 (de) 1996-04-17
WO1991001335A1 (en) 1991-02-07

Similar Documents

Publication Publication Date Title
DE69026615D1 (de) Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest
ES2119369T3 (es) Dispositivo sensor para un ensayo sandwich.
ES2009939A6 (es) Un inmunoensayo para la deteccion simultanea de antigenos yno anticuerpos en una muestra a ensayar de un fluido fisiologico.
DE58902586D1 (de) Immunoassay und -rolymere igg-derivate zur kompensation von stoerfaktoren in immunoassays.
ES512498A0 (es) "metodo y su correspondiente aparato para el ensayo de anticuerpos con respecto a antigenos solubles".
DE3779704D1 (de) Verfahren und testkit zur bestimmung freier wirkstoffe in biologischen fluessigkeiten.
DE3883073D1 (de) Einschritt-immuntest zur bestimmung von antigen-spezifischen antikoerpern aus einer der immunglobulin-klassen a, m, d oder e und dazu geeignetes mittel.
DE3576854D1 (de) Immunchemisches messverfahren fuer haptene und proteine.
DE69106002D1 (de) Testverfahren und reagenziensatz dafür.
DE69124511D1 (de) Verfahren für den nachweis und/oder die bestimmung von hormonen
ES2070488T3 (es) Procedimiento para la deteccion de enfermedades malignas.
Van Toorenenbergen et al. IgG4 and release of histamine from human peripheral blood leukocytes
DE59509344D1 (de) Antikörperklassenspezifisches entstörungsreagenz
ES2141348T3 (es) Metodo de deteccion de la presencia de una especie de mycobacterium, kit y anticuerpos utilizados en este metodo.
KR930008462A (ko) 치주질환과 관련된 미생물의 검증방법에서 높은 pH에서의 추출로 단백질을 보호하는 용도 및 이에 유용한 키트
ATE282830T1 (de) Immuntest für human chromogranine a (cga), antikörper, reagenz und dazu geeigneter testsatz
Reid et al. Biological and chemical differences among proteins having reaginic activity
DE3686717D1 (de) Immuntestverfahren.
ATE188551T1 (de) Feststellung von antikörperproduktion
ATA261687A (de) Laktoferrin enthaltendes inkubationsmedium für festphasen-immunometrische verfahren und seine verwendung
DK608789D0 (da) Cea-immunanalyse uden falske positive foraarsaget af humant anti-museantistof
DE69533904D1 (de) Chemische Modifikation von Antikörpern und Antigenen
DE69333201D1 (de) Vorrichtung und Test zur Bestimmung eines Antigens oder eines Antikörpers in einer Testprobe
ATE323284T1 (de) Assay zur identifikation von ige-antikörper- suppressoren
DE3863270D1 (de) Immuntest.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: STATENS INSTITUTT FOR FOLKEHELSE, OSLO, NO

8339 Ceased/non-payment of the annual fee